Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of neural transmission. Supplementum

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/978-3-211-45295-0_69PMID 17017568
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?

  2006cited by this paper
• Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition

  2005cited by this paper
• Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.

  2005cited by this paper
• Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders.

  2005cited by this paper
• Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease

  2005cited by this paper
• A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.

  2005cited by this paper
• Regulation of Bcl‐2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine

  2005cited by this paper
• Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition

  2005cited by this paper
• N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor.

  2004cited by this paper
• Regulation of protein kinase C by the anti‐Parkinson drug, MAO‐B inhibitor, rasagiline and its derivatives, in vivo

  2004cited by this paper
• Neuroprotection via pro‐survival protein kinase C isoforms associated with Bcl‐2 family members

  2004cited by this paper
• N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-κB transcription factor

  2004cited by this paper
• A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.

  2004cited by this paper
• Iron, brain ageing and neurodegenerative disorders

  2004cited by this paper
• Rasagiline: an anti-Parkinson drug with neuroprotective activity

  2003cited by this paper
• The metallobiology of Alzheimer's disease.

  2003cited by this paper
• Suppression of Protein Kinase C&agr; Triggers Apoptosis Through Down-Regulation of BCL-XL in a Rat Hepatic Epithelial Cell Line

  2003influential reference
• The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline.

  2003cited by this paper
• The importance of propargylamine moiety in the anti‐ Parkinson drug rasagiline and its derivatives for MAPK‐ dependent amyloid precursor protein processing

  2003cited by this paper
• Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory.

  2003cited by this paper
• The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells

  2002cited by this paper
• Mitochondrial permeability transition mediates apoptosis induced by N‐methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl‐2 and rasagiline, N‐propargyl‐1(R)‐aminoindan

  2002cited by this paper
• Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes.

  2002cited by this paper
• The involvement of mitogen‐activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline

  2002cited by this paper
• The Bcl2 family: regulators of the cellular life-or-death switch

  2002cited by this paper
• Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease

  2002influential reference
• Transfection‐enforced Bcl‐2 overexpression and an anti‐Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde‐3‐phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N‐methyl(R)salsolinol

  2001cited by this paper
• A mitochondrial perspective on cell death.

  2001cited by this paper
• Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease.

  2001cited by this paper
• Molecular Basis of Neuroprotective Activities of Rasagiline and the Anti-Alzheimer Drug TV3326 [lpar;N-Propargyl-(3R) Aminoindan-5-YL)-Ethyl Methyl Carbamate]

  2001cited by this paper
• Antiapoptotic Properties of Rasagiline, N‐Propargylamine‐1(R)‐aminoindan, and Its Optical (S)‐Isomer, TV1022

  2001cited by this paper
• Rasagiline [N‐propargyl‐1R(+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

  2001cited by this paper
• BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis.

  2001cited by this paper
• Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa

  2000cited by this paper
• Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022.

  2000cited by this paper
• Mitochondrial control of cell death

  2000cited by this paper
• p90RSK Blocks Bad-mediated Cell Death via a Protein Kinase C-dependent Pathway*

  1999cited by this paper
• Regulation of Amyloid Precursor Protein Cleavage

  1999cited by this paper
• Pharmacology of rasagiline (N-propargyl-1R-aminoindan).

  1999cited by this paper
• Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat

  1999cited by this paper
• Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse.

  1999cited by this paper
• A matter of life and cell death.

  1998cited by this paper
• A Functional Role for Mitochondrial Protein Kinase Cα in Bcl2 Phosphorylation and Suppression of Apoptosis*

  1998cited by this paper
• Overexpression of protein kinase C isoform epsilon but not delta in human interleukin-3-dependent cells suppresses apoptosis and induces bcl-2 expression.

  1998cited by this paper
• The Bcl-2 protein family: arbiters of cell survival.

  1998cited by this paper
• Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins

  1998cited by this paper
• Overexpression of Protein Kinase C Isoform but not δ in Human Interleukin-3–Dependent Cells Suppresses Apoptosis and Induces bcl-2 Expression

  1998cited by this paper
• Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture.

  1997influential reference
• Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance.

  1996cited by this paper
• PC12 cells as a window for the differentiation of neural crest into adrenergic nerve ending and adrenal medulla.

  1991cited by this paper
• Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B.

  1985cited by this paper

• HIST3H2A promotes the progression of prostate cancer through inhibiting cell necroptosis

  2024cites this paper
• Emerging targets signaling for inflammation in Parkinson’s disease drug discovery

  2022cites this paper
• Privileged multi-target directed propargyl-tacrines combining cholinesterase and monoamine oxidase inhibition activities

  2022cites this paper
• Improvement effect of acupuncture on locomotor function in Parkinson disease via regulating gut microbiota and inhibiting inflammatory factor release

  2022cites this paper
• Monoamine oxidases in age-associated diseases: New perspectives for old enzymes.

  2021cites this paper
• Regulation | Monoamine Oxidases

  2021cites this paper
• Essential Oils as a Potential Neuroprotective Remedy for Age-Related Neurodegenerative Diseases: A Review

  2021cites this paper
• Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson’s disease

  2020cites this paper
• A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review.

  2020cites this paper
• Shaping the Nrf2-ARE-related pathways in Alzheimer's and Parkinson's diseases.

  2019cites this paper
• Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease

  2018cites this paper
• MONOAMINE OXIDASE AND ITS INHIBITORS CORRELATING TO NEURODEGENERATIVE DISORDERS (REVIEW)

  2017cites this paper
• Substantial protection against MPTP‐associated Parkinson's neurotoxicity in vitro and in vivo by anti‐cancer agent SU4312 via activation of MEF2D and inhibition of MAO‐B

  2017cites this paper
• Evaluation of selected dye compounds as inhibitors of monoamine oxidase

  2017cites this paper
• Plasmalogen precursor mitigates striatal dopamine loss in MPTP mice.

  2017cites this paper
• Newly Developed Drugs for Alzheimer's Disease in Relation to Energy Metabolism, Cholinergic and Monoaminergic Neurotransmission.

  2017cites this paper
• Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors.

  2016cites this paper
• Rasagiline and selegiline suppress calcium efflux from mitochondria by PK11195-induced opening of mitochondrial permeability transition pore: a novel anti-apoptotic function for neuroprotection

  2015cites this paper
• Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease.

  2015cites this paper
• Evaluation of the Inhibitory Effects of Bavachinin and Bavachin on Human Monoamine Oxidases A and B

  2015cites this paper
• Brain catalase in the streptozotocin-rat model of sporadic Alzheimer’s disease treated with the iron chelator–monoamine oxidase inhibitor, M30

  2015cites this paper
• Exploring heterocyclic scaffolds in the development of multi-target anti-Alzheimer and multi-trypanosomatid compounds

  2015influential citation
• Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review).

  2014cites this paper
• Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease.

  2013influential citation
• Propargylamine-derived multitarget-directed ligands: fighting Alzheimer’s disease with monoamine oxidase inhibitors

  2013cites this paper
• Rationally designed multi-targeted agents against neurodegenerative diseases.

  2013cites this paper
• Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms

  2013cites this paper
• Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders

  2013cites this paper
• A Novel Role for BDNF-TrkB in the Regulation of Chemotherapy Resistance in Head and Neck Squamous Cell Carcinoma

  2012cites this paper
• Activation of Wnt/β-catenin Pathway by Exogenous Wnt1 Protects SH-SY5Y Cells Against 6-Hydroxydopamine Toxicity

  2012cites this paper
• Serotonin receptor subtypes functional regulation and oxidative stress mediated apoptosis in 6 hydroxydopamine lesioned parkinsonian rats functional recovery with serotonin GABA and bone marrow cells

  2012cites this paper
• Behavioral and Immunological Phenotypes of Transgenic Mice Overexpressing Human Secreted Amyloid Precursor Protein Alpha: Implications for Autism

  2012cites this paper
• Study of new propargylamine and donepezil-derived compounds as multitarget agents for the treatment of alzheimer’s disease

  2011cites this paper
• Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl-β-carboline: a new anti-Parkinson drug?

  2011cites this paper
• Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease.

  2011cites this paper
• Blueberry treatment antagonizes C-2 ceramide-induced stress signaling in muscarinic receptor-transfected COS-7 cells.

  2010cites this paper
• Akt signal transduction dysfunction in Parkinson's disease.

  2009cites this paper
• Prenyloxyphenylpropanoids as a novel class of anticonvulsive agents.

  2009cites this paper
• Restoration of Nigrostriatal Dopamine Neurons in Post-MPTP Treatment by the Novel Multifunctional Brain-Permeable Iron Chelator-Monoamine Oxidase Inhibitor Drug, M30

  2009cites this paper
• Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson’s disease drug, rasagiline compared with selegiline, in the rat midbrain

  2009cites this paper
• Neuroprotective effect of prenyloxycoumarins from edible vegetables.

  2008cites this paper
• Protein kinase Cε: the mitochondria‐mediated signaling pathway

  2008cites this paper
• The neuroprotective mechanism of action of the multimodal drug ladostigil.

  2008cites this paper
• PC12 Cells as a model for parkinson's disease research

  2008cites this paper
• Activation of the extracellular signal‐regulated kinases 1 and 2 by glial cell line‐derived neurotrophic factor and its relation to neuroprotection in a mouse model of Parkinson's disease

  2008cites this paper
• Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin‐induced nigrostriatal dopaminergic degeneration

  2008cites this paper
• Effects of Hypoxia and Oxidative Stress on Expression of Neprilysin in Human Neuroblastoma Cells and Rat Cortical Neurones and Astrocytes

  2007cites this paper
• Aging modifies brain region-specific vulnerability to experimental oxidative stress induced by low dose hydrogen peroxide

  2007cites this paper
• MHP-133, a Drug with Multiple CNS Targets: Potential for Neuroprotection and Enhanced Cognition

  2007cites this paper
• Induction of Neurotrophic Factors GDNF and BDNF Associated with the Mechanism of Neurorescue Action of Rasagiline and Ladostigil

  2007cites this paper
• [Neurodegeneration in experimental stroke--involvement of apoptosis-regulating proteins].

  2007cites this paper
• Parkinson’s Disease and Related Disorders

  2006cites this paper